Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB)
Phase of Trial: Phase III
Latest Information Update: 26 Nov 2019
Price : $35 *
At a glance
- Drugs Delamanid (Primary) ; Isoniazid (Primary) ; Pyridoxine
- Indications Pulmonary tuberculosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms PHOENIx MDR-TB
- 21 Jun 2019 Planned End Date changed from 10 Apr 2023 to 18 Jun 2025.
- 21 Jun 2019 Planned primary completion date changed from 10 Apr 2023 to 18 Jun 2025.
- 07 Jun 2019 Status changed from not yet recruiting to recruiting.